Objective:To explore the efficacy of modified Wuhutang combined with azithromycin in treating children with phlegm heat closed lung type mycoplasma pneumoniaand and its effect on T lymphocyte subsets. Method:A total of 150 children with phlegm heat closed lung type mycoplasma pneumonia treated at our hospital from January 2015 to February 2017 were selected as research objectives and randomly divided into two groups

with 75 cases in each group. Azithromycin was provided to both groups; besides

modified Wuhutang was additionally administered to observation group. The two groups' clinical efficacy

T lymphocyte subsets and inflammatory cytokines before and after treatment were compared. Result:After 14 days of treatment

observation group's total effective rate was 98.67%

which was significantly higher than 88.00% of control group (P<0.01). Observation group's dry and wet rales

cough disappearance time and fever time were significantly shorter than those in control group (P<0.01). After 14 days of treatment

the two groups' CD4+ level

CD4+/CD8+ increased significantly (P<0.01)

particularly in observation group (P<0.01). Observation group's CD8+ level decreased significantly (P<0.01)

but there was no obvious change in control group. The two groups' serum interleukin-6

interleukin-8

tumor necrosis factor-α after 14 day of treatment was significantly lower than those before treatment

particularly in observation group (P<0.01). There was no significant adverse drug reaction in the two groups

and the incidence of adverse reactions in observation group was significantly lower than that in control group (P<0.01). Conclusion:Modified Wuhutang combined with azithromycin can effectively reduce inflammatory response and improve immune function of children with phlegm heat closed lung type mycoplasma pneumonia.